<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   Pathfinder Cell Therapy, Inc.
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        803050384
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       45890
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       3
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   Pathfinder Cell Therapy (formerly SyntheMed) keeps surgery patients and disease sufferers off the path towards scarring and organ damage. The company develops polymers aimed at preventing or reducing post-operative adhesions (scar tissue) for a variety of surgical procedures. Its REPEL-CV product, used to prevent the formation of scar tissue in open heart surgeries, is marketed internationally and is approved for use in pediatric cardiac surgeries in the US. The firm added development-stage tissue regeneration products for diabetics and others at risk of organ damage through its 2011 merger with biotech firm Pathfinder LLC; its name changed from SyntheMed to Pathfinder Cell Therapy following the merger.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
